Inhaled and oral bronchodilator therapy in exercise induced asthma

Measurements of peak expiratory flow rate during serial exercise tests were used to assess the efficacy of the beta adrenergic stimulants oral terbutaline (5 mg) and fenoterol aerosol (400 micrograms), in preventing post-exercise bronchoconstriction in 18 asthmatic subjects. While both compounds significantly elevated resting levels of peak expiratory flow rate for at least four hours, there were qualitative and quantitative differences in the effects of the two drugs on exercise induced bronchoconstriction. Oral terbulation did not significantly alter the pattern of response to exercise. However, the peak expiratory flow rates before during and after exercise were significantly higher compared with placebo at two, four and six hours after the drug. The importance of examination of actual values for peak expiratory flow rates as well as percentage changes when testing oral bronchodilators is emphasised. Aerosol fenoterol completely blocked post-exercise bronchoconstriction immediately after inhalation and for up to four hours in most subjects. Bronchodilatation occurred in all subjects during exercise in the presence of both the active and placebo drugs. It is postulated that the superiority of the aerosol in blocking exercise induced bronchoconstriction may be function of its activity at the surface of the bronchial mucosa.     

Effects of aerosol heating rate on the properties of aggregates of lead zirconate titanate nanoparticles produced by spray pyrolysis

The dependence of the shape and size distribution of aggregates of lead zirconate titanate nanoparticles prepared by spray pyrolysis of a sol–gel precursor solution is reported. Decreasing the average heating rate from 300 to 160 °C s⁻¹ in the sub-200 °C section of the reactor decreased the proportion of non-spherical particle aggregates and decreased the maximum size from ~10 to ~5 μm. Microtome sectioning revealed an internal structure composed of <100 nm primary particles. Both solid and hollow particle aggregates were present.     

Thrombolytic therapy in stroke. What do clinical tests prove?

Despite the increased risk of intracranial haemorrhage associated with the use of thrombolytic treatment of stroke. American studies have shown patients treated with rt-PA (recombinant plasminogen activator) within three hours of the onset of symptoms to manifest 30 per cent less disability at three-month follow-up than those placebo. However, until satisfactory criteria for the use of rt-PA are available, caution is essential, and thrombolytic therapy should be restricted to specialised centres. It is also important to promote public awareness of the stroke patient's need of immediate treatment at a specialised stroke unit.